Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis
Launched by XUEBO LIU · Jan 2, 2025
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying new blood tests, called serum biomarkers, to help doctors better identify a condition called plaque erosion in patients with acute coronary syndrome (ACS). This condition can lead to serious heart problems, and the goal is to find ways to diagnose it without needing invasive procedures. The trial will also look at how these biomarkers can help predict a patient’s future health after experiencing ACS. Participants will be contacted for follow-up evaluations at 1, 2, and 5 years after being diagnosed.
To be eligible for this study, participants should be between 65 and 85 years old and have experienced an acute coronary syndrome event, such as a heart attack, and then underwent a procedure to open blocked arteries. However, there are some people who cannot join, such as those under 18 or with certain medical conditions that could complicate the study. If you choose to participate, you can expect to provide blood samples and follow-up information about your health over the coming years. This study is currently recruiting participants and aims to improve heart disease diagnosis and treatment for everyone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • people presenting with an acute coronary syndrome (ACS)-either non-ST-segment elevation myocardial infarction (NSTE-ACS); or ST-segment elevation myocardial infarction (STE-ACS), and subsequently underwent emergent coronary angiography followed by percutaneous coronary intervention (PCI). Culprit leisions were tested using optical coheren tomograpgy and pathological diagnosis(PE OR PR) were validated by 2 independent experienced core lab members.
- Exclusion Criteria:
- • patients younger than 18 years or older than 85 years
- • patients in cardiogenic shock
- • prior coronary artery bypass grafting,
- • patients with corornary stent thrombosis
- • patients with left main coronary disease
- • patients with congestive heart failure
- • patients with life-threatening arrhythmia
- • patients with thrombocytopenia patients with significant hepatic or renal impairment
- • patients with septicemia, leukopenia, active inflammatory or malignant disease
- • other factors compromising high-quality optical coherence tomography (OCT) imaging (e.g., severe vessel tortuosity or calcification, persistent no-reflow, lesions in distal segments, or an indeterminate culprit lesion)
- • Individuals unable to provide informed consent were also excluded.
About Xuebo Liu
Xuebo Liu is a dedicated clinical trial sponsor with extensive expertise in advancing innovative therapeutic solutions. Committed to enhancing patient outcomes, Liu oversees a portfolio of clinical research initiatives that focus on cutting-edge treatments across various medical fields. With a strong emphasis on regulatory compliance and ethical standards, Liu fosters collaboration among multidisciplinary teams to ensure rigorous trial design, implementation, and monitoring. Driven by a passion for scientific discovery, Liu aims to bridge the gap between research and patient care, ultimately contributing to the advancement of medical knowledge and improved health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported